Abstract
Immune checkpoint inhibitors (ICIs) have improved melanoma outcomes but can cause severe immune‐related colitis. Infliximab is often used for steroid‐refractory cases, yet its effect on tumor control remains uncertain. We describe three advanced melanoma patients who developed grade 3–4 colitis after nivolumab plus ipilimumab and were treated with infliximab. Although gastrointestinal symptoms improved, all showed rapid disease progression and died within 3–9 months. These cases suggest that infliximab may compromise antitumor immunity in melanoma patients receiving ICIs.

This publication has 12 references indexed in Scilit: